Children's Hospital of Alabama |
Birmingham, Alabama, United States, 35233 |
Contact: Site Public Contact 205-638-9285 oncologyresearch@peds.uab.edu |
Principal Investigator: Elizabeth D. Alva |
Providence Alaska Medical Center |
Anchorage, Alaska, United States, 99508 |
Contact: Site Public Contact 907-212-6871 AKPAMC.OncologyResearchSupport@providence.org |
Principal Investigator: Brenda J. Wittman |
Banner Children's at Desert |
Mesa, Arizona, United States, 85202 |
Contact: Site Public Contact 480-412-3100 |
Principal Investigator: Joseph C. Torkildson |
Banner University Medical Center - Tucson |
Tucson, Arizona, United States, 85719 |
Contact: Site Public Contact aselegue@email.arizona.edu |
Principal Investigator: Holly E. Pariury |
Arkansas Children's Hospital |
Little Rock, Arkansas, United States, 72202-3591 |
Contact: Site Public Contact 501-364-7373 |
Principal Investigator: David L. Becton |
Kaiser Permanente Downey Medical Center |
Downey, California, United States, 90242 |
Contact: Site Public Contact 626-564-3455 |
Principal Investigator: Robert M. Cooper |
Loma Linda University Medical Center |
Loma Linda, California, United States, 92354 |
Contact: Site Public Contact 909-558-4050 |
Principal Investigator: Albert Kheradpour |
Miller Children's and Women's Hospital Long Beach |
Long Beach, California, United States, 90806 |
Children's Hospital Los Angeles |
Los Angeles, California, United States, 90027 |
Contact: Site Public Contact 323-361-4110 |
Principal Investigator: Fariba Navid |
Valley Children's Hospital |
Madera, California, United States, 93636 |
Contact: Site Public Contact 559-353-3000 Research@valleychildrens.org |
Principal Investigator: Karen S. Fernandez |
UCSF Benioff Children's Hospital Oakland |
Oakland, California, United States, 94609 |
Contact: Site Public Contact 510-428-3324 Carla.Golden@ucsf.edu |
Principal Investigator: Carla B. Golden |
Kaiser Permanente-Oakland |
Oakland, California, United States, 94611 |
Contact: Site Public Contact 877-642-4691 Kpoct@kp.org |
Principal Investigator: Laura A. Campbell |
University of California Davis Comprehensive Cancer Center |
Sacramento, California, United States, 95817 |
Contact: Site Public Contact 916-734-3089 |
Principal Investigator: Marcio H. Malogolowkin |
UCSF Medical Center-Mission Bay |
San Francisco, California, United States, 94158 |
Contact: Site Public Contact 877-827-3222 |
Principal Investigator: Arun A. Rangaswami |
Children's Hospital Colorado |
Aurora, Colorado, United States, 80045 |
Contact: Site Public Contact 303-764-5056 josh.b.gordon@nsmtp.kp.org |
Principal Investigator: Margaret E. Macy |
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center |
Denver, Colorado, United States, 80218 |
Contact: Site Public Contact 303-839-6000 |
Principal Investigator: Jennifer J. Clark |
Yale University |
New Haven, Connecticut, United States, 06520 |
Alfred I duPont Hospital for Children |
Wilmington, Delaware, United States, 19803 |
Contact: Site Public Contact 302-651-6884 dperry@nemours.org |
Principal Investigator: Scott M. Bradfield |
Children's National Medical Center |
Washington, District of Columbia, United States, 20010 |
Contact: Site Public Contact 202-884-2549 |
Principal Investigator: Jeffrey S. Dome |
University of Florida Health Science Center - Gainesville |
Gainesville, Florida, United States, 32610 |
Contact: Site Public Contact 352-273-8010 cancer-center@ufl.edu |
Principal Investigator: William B. Slayton |
Nemours Children's Clinic-Jacksonville |
Jacksonville, Florida, United States, 32207 |
Contact: Site Public Contact 904-697-3529 |
Principal Investigator: Scott M. Bradfield |
University of Miami Miller School of Medicine-Sylvester Cancer Center |
Miami, Florida, United States, 33136 |
Contact: Site Public Contact 305-243-2647 |
Principal Investigator: Julio C. Barredo |
Nicklaus Children's Hospital |
Miami, Florida, United States, 33155 |
Contact: Site Public Contact 888-624-2778 |
Principal Investigator: Enrique A. Escalon |
AdventHealth Orlando |
Orlando, Florida, United States, 32803 |
Contact: Site Public Contact 407-303-2090 FH.Cancer.Research@flhosp.org |
Principal Investigator: Fouad M. Hajjar |
Arnold Palmer Hospital for Children |
Orlando, Florida, United States, 32806 |
Contact: Site Public Contact 321-841-2008 melissa.leffin@orlandohealth.com |
Principal Investigator: Amy A. Smith |
Nemours Children's Hospital |
Orlando, Florida, United States, 32827 |
Contact: Site Public Contact 407-650-7715 |
Principal Investigator: Scott M. Bradfield |
Nemours Children's Clinic - Pensacola |
Pensacola, Florida, United States, 32504 |
Johns Hopkins All Children's Hospital |
Saint Petersburg, Florida, United States, 33701 |
Contact: Site Public Contact 727-767-4784 Ashley.Repp@jhmi.edu |
Principal Investigator: Stacie L. Stapleton |
Saint Joseph's Hospital/Children's Hospital-Tampa |
Tampa, Florida, United States, 33607 |
Contact: Site Public Contact 813-357-0849 jennifer.manns@baycare.org |
Principal Investigator: Don E. Eslin |
Children's Healthcare of Atlanta - Egleston |
Atlanta, Georgia, United States, 30322 |
Contact: Site Public Contact 404-785-2025 Leann.Schilling@choa.org |
Principal Investigator: William T. Cash |
Saint Luke's Cancer Institute - Boise |
Boise, Idaho, United States, 83712 |
Contact: Site Public Contact 208-381-2774 eslinget@slhs.org |
Principal Investigator: Eugenia Chang |
Lurie Children's Hospital-Chicago |
Chicago, Illinois, United States, 60611 |
Contact: Site Public Contact 773-880-4562 |
Principal Investigator: David O. Walterhouse |
University of Chicago Comprehensive Cancer Center |
Chicago, Illinois, United States, 60637 |
Contact: Site Public Contact 773-702-8222 cancerclinicaltrials@bsd.uchicago.edu |
Principal Investigator: Susan L. Cohn |
Saint Jude Midwest Affiliate |
Peoria, Illinois, United States, 61637 |
Contact: Site Public Contact 888-226-4343 |
Principal Investigator: Jaime M. Libes |
Southern Illinois University School of Medicine |
Springfield, Illinois, United States, 62702 |
Riley Hospital for Children |
Indianapolis, Indiana, United States, 46202 |
Contact: Site Public Contact 800-248-1199 |
Principal Investigator: Sandeep Batra |
Blank Children's Hospital |
Des Moines, Iowa, United States, 50309 |
Contact: Site Public Contact 515-241-8912 samantha.mallory@unitypoint.org |
Principal Investigator: Samantha L. Mallory |
University of Iowa/Holden Comprehensive Cancer Center |
Iowa City, Iowa, United States, 52242 |
Contact: Site Public Contact 800-237-1225 |
Principal Investigator: Mariko Sato |
Norton Children's Hospital |
Louisville, Kentucky, United States, 40202 |
Contact: Site Public Contact 502-629-5500 CancerResource@nortonhealthcare.org |
Principal Investigator: Ashok B. Raj |
Children's Hospital New Orleans |
New Orleans, Louisiana, United States, 70118 |
Contact: Site Public Contact CHResearch@lcmchealth.org |
Principal Investigator: Lolie C. Yu |
Ochsner Medical Center Jefferson |
New Orleans, Louisiana, United States, 70121 |
Contact: Site Public Contact 504-703-8712 Gregory.Johnstone@ochsner.org |
Principal Investigator: Craig Lotterman |
Eastern Maine Medical Center |
Bangor, Maine, United States, 04401 |
Contact: Site Public Contact 207-973-4274 |
Principal Investigator: Nadine P. SantaCruz |
University of Maryland/Greenebaum Cancer Center |
Baltimore, Maryland, United States, 21201 |
Sinai Hospital of Baltimore |
Baltimore, Maryland, United States, 21215 |
Johns Hopkins University/Sidney Kimmel Cancer Center |
Baltimore, Maryland, United States, 21287 |
Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu |
Principal Investigator: Kenneth J. Cohen |
Massachusetts General Hospital Cancer Center |
Boston, Massachusetts, United States, 02114 |
Contact: Site Public Contact 877-726-5130 |
Principal Investigator: Katherine A. Janeway |
Dana-Farber Cancer Institute |
Boston, Massachusetts, United States, 02215 |
Contact: Site Public Contact 877-442-3324 |
Principal Investigator: Katherine A. Janeway |
C S Mott Children's Hospital |
Ann Arbor, Michigan, United States, 48109 |
Contact: Site Public Contact 800-865-1125 |
Principal Investigator: Rajen Mody |
Helen DeVos Children's Hospital at Spectrum Health |
Grand Rapids, Michigan, United States, 49503 |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org |
Principal Investigator: Kathleen J. Yost |
Bronson Methodist Hospital |
Kalamazoo, Michigan, United States, 49007 |
Contact: Site Public Contact 616-391-1230 crcwm-regulatory@crcwm.org |
Principal Investigator: Kathleen J. Yost |
Children's Hospitals and Clinics of Minnesota - Minneapolis |
Minneapolis, Minnesota, United States, 55404 |
Contact: Site Public Contact 612-813-5193 |
Principal Investiga
July 10, 2017
|
July 11, 2017
|
June 9, 2021
|
July 24, 2017
|
September 30, 2024 (Final data collection date for primary outcome measure)
|
Objective response rate [ Time Frame: From enrollment to the end of treatment, up to 2 years ] A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
|
Objective response rate [ Time Frame: Up to 4 years ] A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
|
|
- Percentage of patients experiencing grade 3 or higher adverse events [ Time Frame: From enrollment to the end of treatment, up to 2 years ]
Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All patients who receive at least one dose of protocol therapy will be considered in the evaluation of toxicity.
- Progression free survival (PFS) [ Time Frame: From the initiation of protocol treatment to the occurrence of disease progression or disease recurrence or death from any cause, assessed up to 5 years ]
Progression free survival will be defined as time from the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause. PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
|
- Incidence of toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 4 years ]
All patients who receive at least one dose of protocol therapy will be considered in the evaluation of toxicity. Toxicity tables will be constructed to summarize the observed incidence by type of toxicity and grade. Toxicity information recorded will include the type, severity, time of onset, time of resolution, and the probable association with the study regimen.
- Progression free survival (PFS) [ Time Frame: From the initiation of protocol treatment to the occurrence of disease progression or disease recurrence or death from any cause, assessed up to 4 years ]
PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.
|
- Pharmacokinetic (PK) parameters [ Time Frame: Pre-dose, 1, 2, 4, 6-8, and 20-24 hours post day 1 dose and pre-dose, 1, 2, 4, and 6-8 hours post day 28 dose of cycle 1 ]
A descriptive analysis of PK parameters will be performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
- Biomarkers as predictors of response to ensartinib [ Time Frame: Up to 4 years ]
Descriptive analysis will be performed and will be summarized with simple summary statistics.
- Changes in tumor genomic profile [ Time Frame: Up to 4 years ]
Approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid will be explored. Descriptive analysis will be performed and will be summarized with simple summary statistics.
|
- Biomarkers as predictors of response to ensartinib [ Time Frame: Up to 4 years ]
Descriptive analysis will be performed and will be summarized with simple summary statistics.
- Changes in tumor genomic profile [ Time Frame: Up to 4 years ]
Approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor DNA will be explored. Descriptive analysis will be performed and will be summarized with simple summary statistics.
- Pharmacokinetic (PK) parameters [ Time Frame: Pre-dose, 1, 2, 4, 6-8, and 20-24 hours post day 1 dose and pre-dose, 1, 2, 4, and 6-8 hours post day 28 dose of course 1 ]
A descriptive analysis of PK parameters will be performed to define systemic exposure, drug clearance, and other pharmacokinetic parameters. The PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).
|
|
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
|
This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
|
PRIMARY OBJECTIVE:
I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with ensartinib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor ALK or ROS1 fusions or that harbor ALK missense mutations.
SECONDARY OBJECTIVES:
I. To estimate the progression free survival in pediatric patients treated with ensartinib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor ALK or ROS1 fusions or that harbor ALK missense mutations.
II. To obtain information about the tolerability of ensartinib in children with relapsed or refractory cancer.
III. To provide preliminary estimates of the pharmacokinetics of ensartinib in children with relapsed or refractory cancer.
EXPLORATORY OBJECTIVES:
I. To evaluate other biomarkers as predictors of response to ensartinib and specifically, whether tumors that harbor different missense mutations or fusions (including the crizotinib resistant F1174L ALK variant) will demonstrate differential response to ensartinib treatment.
II. To explore approaches to profiling changes in tumor genomics over time through evaluation of circulating tumor deoxyribonucleic acid (DNA).
OUTLINE:
Patients receive ensartinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
|
Interventional
|
Phase 2
|
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment
|
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent WHO Grade II Glioma
- Refractory Ependymoma
- Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Wilms Tumor
|
- Drug: Ensartinib
Given PO
Other Name: X-396
- Other: Laboratory Biomarker Analysis
Correlative studies
- Other: Pharmacological Study
Correlative studies
|
Experimental: Treatment (ensartinib)
Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
Interventions:
- Drug: Ensartinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Not Provided
|
|
Recruiting
|
98
|
Same as current
|
September 30, 2024
|
September 30, 2024 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621F based on the presence of an actionable mutation
- Patients must have a body surface area >= 0.5 m^2 at enrollment
-
Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have iobenguane (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI) and visible on more than one slice
-
Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age
- Note: Neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
-
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
- Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive: >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
- Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil counts [ANC] counts): >= 7 days after the last dose of agent
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid
- Hematopoietic growth factors: >=14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator
- Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)
-
Stem cell Infusions (with or without total body irradiation [TBI]):
- Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)
- Autologous stem cell infusion including boost infusion: >= 42 days
- Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer [NK] cells, dendritic cells, etc.)
-
Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial none marrow (BM) radiation
- Note: Radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment
- Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy
- Patients must not have received prior exposure to ensartinib; prior treatment with other ALK inhibitors is permitted given that at least 5 half-lives or 21 days have elapsed since therapy discontinuation, whichever is greater
-
For patients with solid tumors without known bone marrow involvement:
- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
- Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 (within 7 days prior to enrollment) or a serum creatinine based on age/gender as follows (within 7 days prior to enrollment):
- Age 1 to < 2 years: maximum serum creatinine 0.6 mg/dL for male and 0.6 mg/dL for female
- Age 2 to < 6 years: maximum serum creatinine 0.8 mg/dL for male and 0.8 mg/dL for female
- Age 6 to < 10 years: maximum serum creatinine 1 mg/dL for male and 1 mg/dL for female
- Age 10 to < 13 years: maximum serum creatinine 1.2 mg/dL for male and 1.2 mg/dL for female
- Age 13 to < 16 years: maximum serum creatinine 1.5 mg/dL for male and 1.4 mg/dL for female
- Age >= 16 years: maximum serum creatinine 1.7 mg/dL for male and 1.4 mg/dL for female
- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)
- Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment) (for the purpose of this study, the ULN for SGPT is 45 U/L)
- Serum albumin >= 2 g/dL (within 7 days prior to enrollment)
- Patients must be able to swallow intact capsules
- All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
Exclusion Criteria:
- Pregnant or breast-feeding women will not be entered on this study because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for one week after the last dose of ensartinib
-
Concomitant medications
- Patients who have an uncontrolled infection are not eligible
- Patients who have received a prior solid organ transplantation are not eligible
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
|
Sexes Eligible for Study: |
All |
|
12 Months to 21 Years (Child, Adult)
|
No
|
|
Puerto Rico, United States
|
|
|
NCT03213652
|
NCI-2017-01243 NCI-2017-01243 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) APEC1621F APEC1621F ( Other Identifier: Children's Oncology Group ) APEC1621F ( Other Identifier: CTEP ) U10CA180886 ( U.S. NIH Grant/Contract )
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
Not Provided
|
National Cancer Institute (NCI)
|
National Cancer Institute (NCI)
|
Children's Oncology Group
|
Principal Investigator: |
Meredith S Irwin |
Children's Oncology Group |
|
National Cancer Institute (NCI)
|
March 2021
|
|